Both the disease presentation and evidence from basic studies suggest more than one pathogenetic mechanism is involved in Behçet syndrome. Recognized vascular manifestations in Behçet syndrome include venous claudication, bronchial arterial collaterals (causing haemoptysis) and 'silent' Budd–Chiari syndrome
The diagnostic specificity of certain manifestations, such as eye disease or vascular involvement, might be more pathognomonic than other manifestations, such as gastrointestinal ulcerations
In considering the clinical and the basic science findings in Behçet syndrome, the weight of evidence suggests Behçet syndrome should not to be grouped with other, seemingly related, conditions
The presence of symptom clusters, regional differences in disease expression and similarities with, for example, Crohn's disease suggest multiple pathological pathways are involved in Behçet syndrome. These features also make formulating disease criteria difficult. Genetic studies have identified HLA-B*51 to be the important genetic risk factor. However, the low prevalence of HLA-B*51 in many patients with bone fide disease, especially in non-endemic regions, suggests other factors must also be operative in Behçet syndrome. This consideration is also true for the newly proposed 'MHC-I-opathy' concept. Despite lacking a clear aetiological mechanism and definition, management of manifestations that include major vascular disease (such as Budd–Chiari syndrome and pulmonary artery involvement), eye disease and central nervous system involvement has improved with the help of new technology. Furthermore, even with our incomplete understanding of disease mechanisms, the prognoses of patients with Behçet syndrome, including those with eye disease, continue to improve.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 335, 1078–1080 (1990).
Skef, W. Gastrointestinal Behçet's disease: a review. World J. Gastroenterol. 21, 3801 (2015).
Davatchi, F. et al. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J. Eur. Acad. Dermatol. Venereol. 28, 338–347 (2013).
Yazici, H. & Yazici, Y. Diagnosis and/or classification of vasculitis. Curr. Opin. Rheumatol. 28, 3–7 (2016).
Yazici, H., Ugurlu, S. & Seyahi, E. Behçet syndrome: is it one condition? Clin. Rev. Allergy Immunol. 43, 275–280 (2012).
Tunc, R., Saip, S., Siva, A. & Yazici, H. Cerebral venous thrombosis is associated with major vessel disease in Behçet's syndrome. Ann. Rheum. Dis. 63, 1693–1694 (2004).
Tunc, R., Keyman, E., Melikoglu, M., Fresko, I. & Yazici, H. Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. J. Rheumatol. 29, 2393–2396 (2002).
Tugal-Tutkun, I., Onal, S., Ozyazgan, Y., Soylu, M. & Akman, M. Validity and agreement of uveitis experts in interpretation of ocular photographs for diagnosis of Behçet uveitis. Ocul. Immunol. Inflamm. 22, 461–468 (2013).
Mat, M. C., Goksugur, N., Engin, B., Yurdakul, S. & Yazici, H. The frequency of scarring after genital ulcers in Behçet's syndrome: a prospective study. Int. J. Dermatol. 45, 554–556 (2006).
Kural-Seyahi, E. et al. The long-term mortality and morbidity of Behçet syndrome. Medicine 82, 60–76 (2003).
Yavuz, S. et al. Activation of neutrophils by testosterone in Behçet's disease. Clin. Exp. Rheumatol. 25 (Suppl. 45), S46–S51 (2007).
Seyahi, E. et al. Pulmonary artery involvement and associated lung disease in Behçet disease. Medicine 91, 35–48 (2012).
Tascilar, K. et al. Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course. Rheumatology 53, 2018–2022 (2014).
Seyahi, E. et al. An outcome survey of 43 patients with Budd-Chiari syndrome due to Behçet's syndrome followed up at a single, dedicated center. Semin. Arthritis Rheum. 44, 602–609 (2015).
Melikoglu, M., Kural-Seyahi, E., Tascilar, K. & Yazici, H. The unique features of vasculitis in Behçet's syndrome. Clin. Rev. Allergy Immunol. 35, 40–46 (2008).
Çoban, O. et al. Masked assessment of MRI findings: is it possible to differentiate neuro-Behçet's disease from other central nervous system. Neuroradiology 41, 255–260 (1999).
Siva, A. et al. Behçet's disease: diagnostic and prognostic aspects of neurological involvement. J. Neurol. 248, 95–103 (2001).
Akman-Demir, G., Serdaroglu, P., Tasçi, B. & The Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 122, 2171–2182 (1999).
Valenti, S., Gallizzi, R., De Vivo, D. & Romano, C. Intestinal Behçet and Crohn's disease: two sides of the same coin. Pediatr. Rheumatol. 15, 33 (2017).
Hatemi, I. et al. Frequency of pathergy phenomenon and other features of Behçet's syndrome among patients with inflammatory bowel disease. Clin. Exp. Rheumatol. 26, S91–95.
Takeuchi, M. et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. Nat. Genet. 49, 438–443 (2017).
Hatemi, G., Fresko, I., Tascilar, K. & Yazici, H. Increased enthesopathy among Behçet's syndrome patients with acne and arthritis: An ultrasonography study. Arthritis Rheum. 58, 1539–1545 (2008).
Moll, J. M. H., Haslock, I. A. N., Macrae, I. F. & Wright, V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome. Medicine 53, 343–364 (1974).
McGonagle, D., Aydin, S. Z., Gül, A., Mahr, A. & Direskeneli, H. 'MHC-I-opathy' — unified concept for spondyloarthritis and Behçet disease. Nat. Rev. Rheumatol. 11, 731–740 (2015).
Schett, G. et al. Enthesitis: from pathophysiology to treatment. Nat. Rev. Rheumatol. 13, 731–741 (2017).
Yurdakul, S. et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. 44, 2686–2692 (2001).
Hamuryudan, V. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. Ann. Intern. Med. 128, 443 (1998).
Melikoglu, M. et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J. Rheumatol. 32, 98–105 (2005).
Direskeneli, H. Autoimmunity versus autoinflammation in Behcet's disease: do we oversimplify a complex disorder? Rheumatology 45, 1461–1465 (2006).
Yazici, H. The place of Behçet's syndrome among the autoimmune diseases. Int. Rev. Immunol. 14, 1–10 (1997).
Lule, S. et al. Behçet disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger. J. Autoimmun. 84, 87–96 (2017).
Gul, A. Behçets disease as an autoinflammatory disorder. Curr. Drug Targets Inflamm. Allergy 4, 81–83 (2005).
Franks, W. A. et al. Cytokines in human intraocular inflammation. Curr. Eye Res. 11, 187–191 (1992).
Kirino, Y. et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. Proc. Natl Acad. Sci. USA 110, 8134–8139 (2013).
Yazici, H. & Fresko, I. Behçet's disease and other autoinflammatory conditions: what's in a name? Clin. Exp. Rheumatol. 23 (Suppl. 38), S1–S2 (2005).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01965145 (2017).
Rudwaleit, M. in Rheumatology 5th edn (eds Hochberg, M., Silman, A., Smolen, J., Weinblatt, M. & Weisman, M.) 1123–1127 (Mosby Elsevier, 2011).
Remmers, E. F. et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat. Genet. 42, 698–702 (2010).
Ombrello, M. J. et al. Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc. Natl Acad. Sci. USA 111, 8867–8872 (2014).
Kirino, Y. et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat. Genet. 45, 202–207 (2013).
Evans, D. M. et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat. Genet. 43, 761–767 (2011).
Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 42, 985–990 (2010).
Ambarus, C., Yeremenko, N., Tak, P. P. & Baeten, D. Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Curr. Opin. Rheumatol. 24, 351–358 (2012).
Giza, M., Koftori, D., Chen, L. & Bowness, P. Is Behçet's disease a 'class 1-opathy'? The role of HLA-B*51 in the pathogenesis of Behçet's disease. Clin. Exp. Immunol. 191, 11–18 (2017).
Schwartz, D. M., Bonelli, M., Gadina, M. & O'Shea, J. J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat. Rev. Rheumatol. 12, 25–36 (2015).
Tulunay, A. et al. Activation of the JAK/STAT pathway in Behcet's disease. Genes Immun. 16, 170–175 (2014).
Hatemi, G. & Yazici, H. Behçet's syndrome and micro-organisms. Best Pract. Res. Clin. Rheumatol. 25, 389–406 (2011).
Behçet, H. Über residivierende aphtose, durch ein virus verursachte geschwüre am mund, am auge und den genitalen [German]. Dermatol. Wochenschrift. 105, 1152–1158 (1937).
Mumcu, G., Inanc, N., Yavuz, S. & Direskeneli, H. The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease. Clin. Exp. Rheumatol. 25 (Suppl. 45), S27–S33 (2007).
Coit, P. et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease. Clin. Immunol. 169, 28–35 (2016).
Seoudi, N., Bergmeier, L. A., Drobniewski, F., Paster, B. & Fortune, F. The oral mucosal and salivary microbial community of Behçet's syndrome and recurrent aphthous stomatitis. J. Oral Microbiol. 7, 27150 (2015).
Shimizu, J. et al. Bifidobacteria abundance-featured gut microbiota compositional change in patients with Behcet's disease. PLoS ONE 11, e0153746 (2016).
Consolandi, C. et al. Behçet's syndrome patients exhibit specific microbiome signature. Autoimmun. Rev. 14, 269–276 (2015).
Xavier, J. M. et al. FUT2: filling the gap between genes and environment in Behçet's disease? Ann. Rheum. Dis. 74, 618–624 (2013).
Maroni, L., van de Graaf, S. F. J., Hohenester, S. D., Oude Elferink, R. P. J. & Beuers, U. Fucosyltransferase 2: a genetic risk factor for primary sclerosing cholangitis and Crohn's disease — a comprehensive review. Clin. Rev. Allergy Immunol. 48, 182–191 (2014).
Goto, Y., Uematsu, S. & Kiyono, H. Epithelial glycosylation in gut homeostasis and inflammation. Nat. Immunol. 17, 1244–1251 (2016).
Hughes, T. et al. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behçet's disease. Arthritis Rheumatol. 66, 1648–1658 (2014).
Coit, P., Direskeneli, H. & Sawalha, A. H. An update on the role of epigenetics in systemic vasculitis. Curr. Opin. Rheumatol. 10.1097/bor.0000000000000451 (2017).
Morton, L. T., Situnayake, D. & Wallace, G. R. Genetics of Behçet's disease. Curr. Opin. Rheumatol. 28, 39–44 (2016).
Maldini, C., LaValley, M. P., Cheminant, M., de Menthon, M. & Mahr, A. Relationships of HLA-B51 or B5 genotype with Behçet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology 51, 887–900 (2012).
Becatti, M. et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet's disease. Circulation 133, 302–311 (2015).
Verity, D. H., Marr, J. E., Ohno, S., Wallace, G. R. & Stanford, M. R. Behcet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54, 213–220 (1999).
Ndiaye, M. et al. Behçet's disease in black skin. A retrospective study of 50 cases in Dakar. J. Dermatol. Case Rep. 9, 98–102 (2015).
Mohammad, A., Mandl, T., Sturfelt, G. & Segelmark, M. Incidence, prevalence and clinical characteristics of Behcet's disease in southern Sweden. Rheumatology 52, 304–310 (2012).
Papoutsis, N. G. et al. Prevalence of Adamantiades-Behçet's disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin. Exp. Rheumatol. 24 (Suppl 42), S125 (2006).
Kappen, J. H. et al. Behçet's disease, hospital-based prevalence and manifestations in the Rotterdam area. Neth. J. Med. 73, 471–477 (2015).
Mahr, A. et al. Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 58, 3951–3959 (2008).
Calamia, K. T. et al. Epidemiology and clinical characteristics of behçet's disease in the US: a population-based study. Arthritis Rheum. 61, 600–604 (2009).
Yazici, Y., Filopoulos, M. T., Schimmel, E., McCraken, A. & Swearingen, C. Clinical characteristics, treatment and ethnic/racial differences in the manifestations of 518 Behcet's syndrome patients in the United States [abstract]. Arthritis. Rheum. 62 (Suppl.), 1284 (2010).
Salvarani, C. et al. Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheum. 57, 171–178 (2007).
Madanat, W. Y. et al. The prevalence of Behçet disease in the north of Jordan: a hospital based epidemiological survey. Clin. Exp. Rheumatol 35 (Suppl.), S51–S54 (2017).
Saadoun, D. et al. Mortality in Behçet's disease. Arthritis Rheum. 62, 2806–2812 (2010).
Bernabe, E., Marcenes, W., Mather, J., Phillips, C. & Fortune, F. Impact of Behcet's syndrome on health-related quality of life: influence of the type and number of symptoms. Rheumatology 49, 2165–2171 (2010).
Buyuktas, D. et al. Fatigue is correlated with disease activity but not with the type of organ involvement in Behçet's syndrome: a comparative clinical survey. Clin. Exp. Rheumatol. 33, S107–112.
Ilhan, B. et al. Fatigue in patients with Behcet's syndrome: relationship with quality of life, depression, anxiety, disability and disease activity. Int. J. Rheum. Dis. 10.1111/1756-185X.12839 (2016).
Moses Alder, N., Fisher, M. & Yazici, Y. Behçet's syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). Clin. Exp. Rheumatol. 26 (Suppl. 50), S110–S113 (2008).
Saygin, C., Uzunaslan, D., Hatemi, G. & Hamuryudan, V. Suicidal ideation among patients with Behçet's syndrome. Clin. Exp. Rheumatol. 33 (Suppl. 94), S30–S35 (2015).
Volle, G. et al. Dietary and nondietary triggers of oral ulcer recurrences in Behçet's disease. Arthritis Care Res. 69, 1429–1436 (2017).
Hamuryudan, V. et al. Frequent oral ulceration during early disease may predict a severe disease course in males with Behçet's syndrome. Clin. Exp. Rheumatol. 30 (Suppl. 72), S32–S34 (2012).
Alibaz-Oner, F. et al. Unmet need in Behcet's disease: most patients in routine follow-up continue to have oral ulcers. Clin. Rheumatol. 33, 1773–1776 (2014).
Tugal-Tutkun, I., Ozdal, P. C., Oray, M. & Onal, S. Review for diagnostics of the year: multimodal imaging in Behçet uveitis. Ocul. Immunol. Inflamm. 25, 7–19 (2016).
Onal, S. et al. Quantitative analysis of structural alterations in the choroid of patients with active Behçet uveitis. Retina 10.1097/iae.0000000000001587 (2017).
Oray, M., Onal, S., Bayraktar, S., Izgi, B. & Tugal-Tutkun, I. Nonglaucomatous localized retinal nerve fiber layer defects in Behçet uveitis. Am. J. Ophthalmol. 159, 475–481.e1 (2015).
Chung, Y.-R., Lee, E.-S., Kim, M. H., Lew, H. M. & Song, J. H. Changes in ocular manifestations of Behçet disease in Korean patients over time: a single-center experience in the 1990s and 2000s. Ocul. Immunol. Inflamm. 23, 157–161 (2014).
Cingu, A. K., Onal, S., Urgancioglu, M. & Tugal-Tutkun, I. Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul. Immunol. Inflamm. 20, 423–428 (2012).
Taylor, S. R. J. et al. Behçet disease: visual prognosis and factors influencing the development of visual loss. Am. J. Ophthalmol. 152, 1059–1066 (2011).
Accorinti, M., Pesci, F. R., Pirraglia, M. P., Abicca, I. & Pivetti-Pezzi, P. Ocular Behçet's disease: changing patterns over time, complications and long-term visual prognosis. Ocul. Immunol. Inflamm. 25, 29–36 (2016).
Seyahi, E. et al. Clinical and ultrasonographic evaluation of lower-extremity vein thrombosis in Behcet syndrome. Medicine 94, e1899 (2015).
Seyahi, E. et al. The estimated pulmonary artery pressure can be elevated in Behçet's syndrome. Respir. Med. 105, 1739–1747 (2011).
Esatoglu, S. N. et al. Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behçet's syndrome patients with pulmonary artery involvement during follow-up. Clin. Exp. Rheumatol. 34 (Suppl. 102), 92–96 (2016).
Siva, A. & Saip, S. The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis. J. Neurol. 256, 513–529 (2009).
Gündüz, T. et al. Cognitive impairment in neuro-Behcet's disease and multiple sclerosis: a comparative study. Int. J. Neurosci. 122, 650–656 (2012).
Akman-Demir, G. et al. Behçet's disease patients with multiple sclerosis-like features: discriminative value of Barkhof criteria. Clin. Exp. Rheumatol. 33 (Suppl. 94), S80–S84 (2015).
Kikuchi, H., Takayama, M. & Hirohata, S. Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behçet's disease. J. Neurol. Sci. 337, 80–85 (2014).
Noel, N. et al. Long-term outcome of neuro-Behçet's disease. Arthritis Rheumatol. 66, 1306–1314 (2014).
Hatemi, I. et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet's syndrome. Medicine 95, e3348 (2016).
Esatoglu, S. N. et al. Fecal calprotectin level looks promising in identifying active disease in Behçet's syndrome patients with gastrointestinal involvement: a controlled and pilot study [abstract]. Ann. Rheum. Dis. 75, AB0574 (2016).
Hatemi, G. et al. Outcome measures used in clinical trials for Behcet syndrome: a systematic review. J. Rheumatol. 41, 599–612 (2014).
Hatemi, G. et al. Current status, goals, and research agenda for outcome measures development in Behcet syndrome: report from OMERACT 2014. J. Rheumatol. 42, 2436–2441 (2015).
Hatemi, G. et al. Developing a core set of outcome measures for Behçet disease: report from OMERACT 2016. J. Rheumatol. 44, 1750–1753 (2017).
Cush, J. New EULAR guidelines on Behçet's. RheumNow http://rheumnow.com/content/new-eular-guidelines-beh%C3%A7ets (2016).
Tasli, L., Mat, C., De Simone, C. & Yazici, H. Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Clin. Exp. Rheumatol. 24 (Suppl. 42), S83–S86 (2006).
Hatemi, G. et al. Apremilast for Behçet's syndrome — a phase 2, placebo-controlled study. N. Engl. J. Med. 372, 1510–1518 (2015).
Alpsoy, E. et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch. Dermatol. 138, 467–471 (2002).
Grayson, P. C. et al. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study. Arthritis Res. Ther. 19, 69 (2017).
Mirouse, A. et al. Ustekinumab for Behçet's disease. J. Autoimmun. 82, 41–46 (2017).
Gül, A. et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann. Rheum. Dis. 71, 563–566 (2011).
Tugal-Tutkun, I. et al. Safety and efficacy of gevokizumab in patients with behçet's disease uveitis: results of an exploratory phase 2 study. Ocul. Immunol. Inflamm. 25, 62–70 (2016).
Dick, A. D. et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120, 777–787 (2013).
Deroux, A., Chiquet, C. & Bouillet, L. Tocilizumab in severe and refractory Behcet's disease: four cases and literature review. Semin. Arthritis Rheum. 45, 733–737 (2016).
Eser Ozturk, H., Oray, M. & Tugal-Tutkun, I. Tocilizumab for the treatment of Behçet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy. Ocul. Immunol. Inflamm. 10.1080/09273948.2017.1355471 (2017).
Hamuryudan, V. et al. Pulmonary artery aneurysms in Behçet syndrome. Am. J. Med. 117, 867–870 (2004).
Tuzun, H. et al. Management and prognosis of nonpulmonary large arterial disease in patients with Behçet disease. J. Vasc. Surg. 55, 157–163 (2012).
Hamuryudan, V. et al. Pulmonary artery involvement in Behçet's syndrome: effects of anti-Tnf treatment. Semin. Arthritis Rheum. 45, 369–373 (2015).
Seyahi, E. & Yazici, H. To anticoagulate or not to anticoagulate vascular thrombosis in Behçet's syndrome: an enduring question. Clin. Exp. Rheumatol. 34 (Suppl. 95), S3–S4 (2016).
Alibaz-Oner, F. et al. Behçet disease with vascular involvement. Medicine. 94, e494 (2015).
Akman-Demir, G. et al. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement? Clin. Exp. Rheumatol. 26 (Suppl. 50), S84–S90 (2008).
Hirohata, S. et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet's syndrome. Clin. Immunol. Immunopathol. 82, 12–17 (1997).
Akman-Demir, G. et al. Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine 44, 373–376 (2008).
Hatemi, I., Hatemi, G., Pamuk, O. N., Erzin, Y. & Celik, A. F. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin. Exp. Rheumatol. 33 (Suppl. 94), S129–S137 (2015).
Soysal, T. et al. Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature. Rheumatology 53, 1136–1141 (2014).
Yazici, H. Behçet's syndrome in the 2000s: “Where is the wisdom we have lost in knowledge?” Clin. Exp. Rheumatol. 34, (Suppl. 102) S23–S25 (2016).
Yurdakul, S. & Yazici, Y. in Behçet's Syndrome 1st edn (eds Yazici, Y. & Yazici, H.) 35–52 (Springer, 2010).
The authors thank H. Direskeneli (Marmara University, Turkey) for his valuable comments during manuscript preparation.
E.S. has received honoraria or speaker's fees from Pfizer, MSD, Mustafa Nevzat and UCB Pharma. G.H. has received honoraria, speaker fees and/or research grants from Abbvie, BMS, Celgene, Mustafa Nevzat, MSD, Pfizer and UCB Pharma. Y.Y. has received research grants from BMS, Celgene and Genentech, and has received consulting fees from Celgene. H.Y. declares no competing interests.
About this article
Cite this article
Yazici, H., Seyahi, E., Hatemi, G. et al. Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14, 107–119 (2018). https://doi.org/10.1038/nrrheum.2017.208
Clinical Reviews in Allergy & Immunology (2020)
Behçet’s syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics
Internal and Emergency Medicine (2020)
Clinical Rheumatology (2020)
Expert Opinion on Drug Safety (2020)
JGH Open (2020)